{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"grade 4 NK infusion related toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}],"title":"failure to engraft by D+28 or delayed engraftment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"· grades 3-5 allergic reactions related to study cell infusion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"11"}]}],"title":"grade 3-5 organ toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"grades 3-4 acute GVHD occurring within 45 days post-transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"treatment-related death within 8 weeks of the study cell infusion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"30"}],"units":"Participants"}],"description":"Dose limiting toxicity is defined as number of participants experienced:\n\n* grade 4 NK infusion related toxicity,\n* failure to engraft by D+28 or delayed engraftment,\n* grades 3-5 allergic reactions related to study cell infusion,\n* grade 3-5 organ toxicity (cardiac, dermatologic, gastrointestinal, hepatic, pulmonary, renal/genitourinary, or neurologic) not pre-existing or due to the underlying malignancy or due to preparative chemotherapy and occurring within 30 days (+3 days if necessary) post-transplant,\n* grades 3-4 acute GVHD occurring within 45 days post-transplant,\n* treatment-related death within 8 weeks of the study cell infusion.","groups":[{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG000","title":"P1_C1_5x10^6"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG001","title":"P1_C2_1x10^7"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG002","title":"P1_C3_5x10^7"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG003","title":"P1_C4_1X10^8"},{"description":"Patients receive elotuzumab IV over 2-5 hours on day -15 and -8, lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG004","title":"P2_1x10^8+Elotuzumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Within 30 days post-transplant","title":"Number of Participants With Dose Limiting Toxicities","type":"PRIMARY","unitOfMeasure":"Participants"}